Regulation of T cell trafficking by the T cell immunoglobulin and mucin domain 1 glycoprotein

Trends in Molecular Medicine

Volumn 20, Issue 12, 2014, Pages 675-684

  Angiari, Stefano ^a   Constantin, Gabriela ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Autoimmunity; Inflammation; Leukocyte trafficking; Selectins; TIM 1

Indexed keywords

GLYCOPROTEIN; IMMUNOGLOBULIN; PADGEM PROTEIN; PHOSPHATIDYLSERINE; SELECTIN; HAVCR1 PROTEIN, HUMAN; LIGAND; MEMBRANE PROTEIN; P-SELECTIN LIGAND PROTEIN; VIRUS RECEPTOR;

CELL TRANSPORT; EFFECTOR CELL; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NONHUMAN; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TH1 CELL; TH17 CELL; ANIMAL; AUTOIMMUNITY; DISEASE MODEL; IMMUNOLOGY; INFLAMMATION; LEUKOCYTE ROLLING; LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; LEUKOCYTE ROLLING; LIGANDS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; RECEPTORS, VIRUS; SELECTINS; T-LYMPHOCYTES; TH1 CELLS; TH17 CELLS;

EID: 84915802675     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.10.003     Document Type: Review

References (133)

1. Luster A.D., et al. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 2005, 6:1182-1190.
2. Ley K., et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007, 7:678-689.
3. McEver R.P., Zhu C. Rolling cell adhesion. Annu. Rev. Cell. Dev. Biol. 2010, 26:363-396.
4. Zarbock A., et al. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 2011, 118:6743-6751.
5. Ley K., Kansas G.S. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat. Rev. Immunol. 2004, 4:325-335.
6. Alon R., Feigelson S.W. Chemokine-triggered leukocyte arrest: force-regulated bi-directional integrin activation in quantal adhesive contacts. Curr. Opin. Cell. Biol. 2012, 24:670-676.
7. Rossi B., Constantin G. Anti-selectin therapy for the treatment of inflammatory diseases. Inflamm. Allergy Drug Targets 2008, 7:85-93.
8. Angiari S., Constantin G. Selectins and their ligands as potential immunotherapeutic targets in neurological diseases. Immunotherapy 2013, 5:1207-1220.
9. Angiari S., et al. TIM-1 glycoprotein binds the adhesion receptor P-selectin and mediates T cell trafficking during inflammation and autoimmunity. Immunity 2014, 40:542-553.
10. Rennert P.D. Novel roles for TIM-1 in immunity and infection. Immunol. Lett. 2011, 141:28-35.
11. Rodriguez-Manzanet R., et al. The costimulatory role of TIM molecules. Immunol. Rev. 2009, 229:259-270.
12. Freeman G.J., et al. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol. Rev. 2010, 235:172-189.
13. McIntire J.J., et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat. Immunol. 2001, 2:1109-1116.
14. McIntire J.J., et al. TIM-1, a novel allergy and asthma susceptibility gene. Springer Semin. Immunopathol. 2004, 25:335-348.
15. Wilker P.R., et al. Evidence for carbohydrate recognition and homotypic and heterotypic binding by the TIM family. Int. Immunol. 2007, 19:763-773.
16. Santiago C., et al. Structures of T cell immunoglobulin mucin protein 4 show a metal-ion-dependent ligand binding site where phosphatidylserine binds. Immunity 2007, 27:941-951.
17. Santiago C., et al. Structures of T cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family. Immunity 2007, 26:299-310.
18. Kobayashi N., et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 2007, 27:927-940.
19. DeKruyff R.H., et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J. Immunol. 2010, 184:1918-1930.
20. Miyanishi M., et al. Identification of Tim4 as a phosphatidylserine receptor. Nature 2007, 450:435-439.
21. Nakayama M., et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 2009, 113:3821-3830.
22. Ichimura A., et al. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J. Clin. Invest. 2008, 118:1657-1668.
23. Lee H.H., et al. Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivity. J. Immunol. 2010, 185:5225-5235.
24. Monney L., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415:536-541.
25. Zhu C., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6:1245-1252.
26. Sehrawat S., et al. Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathog. 2010, 10.1371/journal.ppat.1000882.
27. Gao X., et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE 2012, 10.1371/journal.pone.0030676.
28. Gupta S., et al. Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs. J. Clin. Invest. 2012, 122:2395-2404.
29. Gautron A.S., et al. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur. J. Immunol. 2014, 44:2703-2711.
30. Jones R.B., et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 2008, 205:2763-2779.
31. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
32. Anderson A.C., et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007, 318:1141-1143.
33. Chiba S., et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 2012, 13:832-842.
34. Kuchroo V.K., et al. New roles for TIM family members in immune regulation. Nat. Rev. Immunol. 2008, 8:577-580.
35. Nakae S., et al. TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. Blood 2007, 110:2565-2568.
36. Rodriguez-Manzanet R., et al. TIM-4 expressed on APCs induces T cell expansion and survival. J. Immunol. 2008, 180:4706-4713.
37. Rodriguez-Manzanet R., et al. T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8706-8711.
38. Mazaheri F., et al. Distinct roles for BAI1 and TIM-4 in the engulfment of dying neurons by microglia. Nat. Commun. 2014, 10.1038/ncomms5046.
39. Wong K., et al. Phosphatidylserine receptor Tim-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8712-8717.
40. Albacker L.A., et al. TIM-4, a receptor for phosphatidylserine, controls adaptive immunity by regulating the removal of antigen-specific T cells. J. Immunol. 2010, 185:6839-6849.
41. Albacker L.A., et al. TIM-4, expressed by medullary macrophages, regulates respiratory tolerance by mediating phagocytosis of antigen-specific T cells. Mucosal Immunol. 2013, 6:580-590.
42. Baghdadi M., et al. TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. Immunity 2013, 39:1070-1081.
43. Meyers H.J., et al. TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat. Immunol. 2005, 6:455-464.
44. Kaplan G., et al. Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J. 1996, 15:4282-4296.
45. Ichimura B., et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 1998, 273:4135-4142.
46. Mariat C., et al. Tim-1 signaling substitutes for conventional signal 1 and requires costimulation to induce T cell proliferation. J. Immunol. 2009, 182:1379-1385.
47. Binné L.L., et al. Human TIM-1 associates with the TCR complex and up-regulates T cell activation signals. J. Immunol. 2007, 178:4342-4350.
48. Umetsu S.E., et al. TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat. Immunol. 2005, 6:447-454.
49. de Souza A.J., et al. T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17113-17118.
50. Xiao S., et al. Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J. Exp. Med. 2007, 201:1691-1702.
51. Degauque N., et al. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J. Clin. Invest. 2008, 118:735-741.
52. Ueno T., et al. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J. Clin. Invest. 2008, 118:742-751.
53. Yuan X., et al. Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:10734-10739.
54. Ding Q., et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J. Clin. Invest. 2011, 121:3645-3656.
55. Ma J., et al. TIM-1 signaling in B cells regulates antibody production. Biochem. Biophys. Res. Commun. 2011, 406:223-228.
56. Xiao S., et al. Tim-1 stimulation of dendritic cells regulates the balance between effector and regulatory T cells. Eur. J. Immunol. 2011, 41:1539-1549.
57. Kondratowicz A.S., et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:8426-8431.
58. Balasubramanian S., et al. TIM family proteins promote the lysosomal degradation of the nuclear receptor NUR77. Sci. Signal. 2012, 5:ra90. 10.1126/scisignal.2003200.
59. Li M., et al. TIM-family proteins inhibit HIV-1 release. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E3699-E3707.
60. Sizing I.D., et al. Epitope-dependent effect of anti-murine TIM-1 monoclonal antibodies on T cell activity and lung immune responses. J. Immunol. 2007, 178:2249-2261.
61. Encinas J.A., et al. Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma. J. Allergy Clin. Immunol. 2005, 116:1343-1349.
62. Sonar S.S., et al. Antagonism of TIM-1 blocks the development of disease in a humanized mouse model of allergic asthma. J. Clin. Invest. 2010, 120:2767-2781.
63. Uchida Y., et al. The emerging role of T cell immunoglobulin mucin-1 in the mechanism of liver ischemia and reperfusion injury in the mouse. Hepatology 2010, 51:1363-1372.
64. Rong S., et al. The TIM-1:TIM-4 pathway enhances renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 2011, 22:484-495.
65. Nozaki Y., et al. Endogenous Tim-1 (Kim-1) promotes T-cell responses and cell-mediated injury in experimental crescentic glomerulonephritis. Kidney Int. 2012, 81:844-855.
66. Nozaki Y., et al. Endogenous Tim-1 promotes severe systemic autoimmunity and renal disease MRL-Faslpr mice. Am. J. Physiol. Renal Physiol. 2014, 306:F1210-F1221.
67. McIntire J.J., et al. Immunology: hepatitis A virus link to atopic disease. Nature 2003, 425:576.
68. Kim H.Y., et al. A polymorphism in TIM1 is associated with susceptibility to severe hepatitis A virus infection in humans. J. Clin. Invest. 2011, 121:1111-1118.
69. Matricardi P.M., et al. Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. BMJ 1997, 314:999-1003.
70. Matricardi P.M., et al. Hay fever and asthma in relation to markers of infection in the United States. J. Allergy Clin. Immunol. 2002, 110:381-387.
71. Chatenoud L., Bach J.F. Genetic control of hepatitis A severity and susceptibility to allergy. J. Clin. Invest. 2011, 121:848-850.
72. Graves P.E., et al. A cluster of five tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of Caucasian children. Am. J. Res. Crit. Care Med. 2000, 161:A930.
73. Chae S. The association of the exon 4 variations of Tim-1 gene with allergic diseases in a Korean population. Biochem. Biophys. Res. Commun. 2003, 12:346-350.
74. Gao P.S. Genetic variants of the T-cell immunoglobulin mucin 1 but not the T-cell immunoglobulin mucin 3 gene are associated with asthma in an African American population. J. Allergy Clin. Immunol. 2005, 115:982-988.
75. Page N.S., et al. Genetic association studies between the T cell immunoglobulin mucin (TIM) gene locus and childhood atopic dermatitis. Int. Arch. Allergy Immunol. 2006, 141:331-336.
76. Wu Q., et al. Association analysis of TIM-1-232G > A and 5383_5397 insertion/deletion polymorphisms with childhood asthma and total serum immunoglobulin E levels in middle China. J. Investig. Allergol. Clin. Immunol. 2009, 19:146-153.
77. Mou Z., et al. Association between TIM-1 gene polymorphisms and allergic rhinitis in a Han Chinese population. J. Investig. Allergol. Clin. Immunol. 2010, 20:3-8.
78. Chen J.P., et al. Association of hepatitis A exposure and TIM-1 with childhood allergic asthma. J. Asthma 2012, 49:697-702.
79. Mete F., et al. Association between gene polymorphisms in TIM1, TSLP, IL18R1 and childhood asthma in Turkish population. Int. J. Clin. Exp. Med. 2014, 7:1071-1077.
80. Mosbruger T.L., et al. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J. Infect. Dis. 2010, 201:1371-1380.
81. Abad-Molina C., et al. HAVCR1 gene haplotypes and infection by different viral hepatitis C virus genotypes. Clin. Vaccine Immunol. 2012, 19:223-227.
82. Wojcik G., et al. Variants in HAVCR1 gene region contribute to hepatitis C persistence in African Americans. J. Infect. Dis. 2014, 209:355-359.
83. Wichukchinda N., et al. TIM1 haplotype may control the disease progression to AIDS in a HIV-1-infected female cohort in Thailand. AIDS 2010, 24:1625-1631.
84. Sharma G., et al. Status of TIM-1 exon 4 haplotypes and CD4+T cell counts in HIV-1 seroprevalent North Indians. Hum. Immunol. 2013, 74:163-165.
85. Nuchnoi P., et al. Significant association between TIM1 promoter polymorphisms and protection against cerebral malaria in Thailand. Ann. Hum. Genet. 2008, 72:327-336.
86. Chae S.C., et al. The exon 4 variations of Tim-1 gene are associated with rheumatoid arthritis in a Korean population. Biochem. Biophys. Res. Commun. 2004, 315:971-975.
87. Chae S.C., et al. The polymorphisms of Tim-1 promoter region are associated with rheumatoid arthritis in a Korean population. Immunogenetics 2005, 56:696-701.
88. García-Lozano J.R., et al. Identification of HAVCR1 gene haplotypes associated with mRNA expression levels and susceptibility to autoimmune diseases. Hum. Genet. 2010, 128:221-229.
89. Xu J.R., et al. Polymorphisms of the TIM-1 gene are associated with rheumatoid arthritis in the Chinese Hui minority ethnic population. Genet. Mol. Res. 2012, 11:61-69.
90. Khademi M., et al. T cell Ig- and mucin domain- containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J. Immunol. 2004, 172:7169-7176.
91. Li F., et al. Post-translational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin. J. Biol. Chem. 1996, 271:3255-3264.
92. Gorfu G., et al. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr. Mol. Med. 2009, 9:836-850.
93. Berg E.L., et al. L-selectin-mediated lymphocyte rolling on MAdCAM-1. Nature 1993, 366:695-698.
94. Berlin C., et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993, 74:185-195.
95. Yamanishi Y., et al. TIM1 is an endogenous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury. J. Exp. Med. 2010, 207:1501-1511.
96. Xiao S., et al. Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-mutant mice. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:12105-12110.
97. Steegmaier M., et al. The E-selectin-ligand ESL-1 is located in the Golgi as well as on microvilli on the cell surface. J. Cell Sci. 1997, 110:687-694.
98. Ledbetter J.A., et al. Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:1384-1388.
99. D'Ambrosio D., et al. Concurrency in leukocyte vascular recognition: developing the tools for a predictive computer model. Trends Immunol. 2004, 8:411-416.
100. Montresor A., et al. Chemokines and the signaling modules regulating integrin affinity. Front. Immunol. 2012, 3:127.
101. Montresor A., et al. JAK tyrosine kinases promote hierarchical activation of Rho and Rap modules of integrin activation. J. Cell Biol. 2013, 203:1003-1011.
102. Wilkins P.P., et al. Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin. J. Biol. Chem. 1995, 270:22677-22680.
103. Norman K.E., et al. Leukocyte rolling in vivo is mediated by P-selectin glycoprotein ligand-1. Blood 1995, 86:4417-4421.
104. Xia L., et al. P-selectin glycoprotein ligand-1-deficient mice have impaired leukocyte tethering to E-selectin under flow. J. Clin. Invest. 2002, 109:939-950.
105. Hirata T., et al. P-selectin glycoprotein ligand 1 (PSGL-1) is a physiological ligand for E-selectin in mediating T helper 1 lymphocyte migration. J. Exp. Med. 2000, 192:1669-1676.
106. Sperandio M., et al. P selectin glycoprotein ligand-1 mediates L selectin-dependent leukocyte rolling in venules. J. Exp. Med. 2003, 197:1355-1363.
107. Nácher M., et al. Physiological contribution of CD44 as a ligand for E-selectin during inflammatory T-cell recruitment. Am. J. Pathol. 2011, 178:2437-2446.
108. Matsumoto M., et al. CD43 collaborates with P-selectin glycoprotein ligand-1 to mediate E-selectin-dependent T cell migration into inflamed skin. J. Immunol. 2007, 178:2499-2506.
109. Yang J., et al. Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J. Exp. Med. 1999, 190:1769-1782.
110. León B., Ardavín C. Monocyte migration to inflamed skin and lymph nodes is differentially controlled by L-selectin and PSGL-1. Blood 2008, 111:3126-3130.
111. Austrup F., et al. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 1997, 385:81-83.
112. Mangan P.R., et al. Both Th1 and Th2 cells require P-selectin glycoprotein ligand-1 for optimal rolling on inflamed endothelium. Am. J. Pathol. 2005, 167:1661-1675.
113. Veerman K.M., et al. Interaction of the selectin ligand PSGL-1 with chemokines CCL21 and CCL19 facilitates efficient homing of T cells to secondary lymphoid organs. Nat. Immunol. 2007, 8:532-539.
114. Constantin G. PSGL-1 as a novel therapeutic target. Drug News Perspect. 2004, 17:579-586.
115. Doebis C., et al. Cellular players and role of selectin ligands in leukocyte recruitment in a T-cell-initiated delayed-type hypersensitivity reaction. Am. J. Pathol. 2008, 173:1067-1076.
116. Martin T.A., et al. HAVcR-1 reduces the integrity of human endothelial tight junctions. Anticancer Res. 2011, 31:467-473.
117. Wang H.B., et al. P-selectin primes leukocyte integrin activation during inflammation. Nat. Immunol. 2007, 8:882-892.
118. de Souza A.J., et al. T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase. J. Immunol. 2008, 180:6518-6526.
119. Curtiss M.L., et al. Fyn binds to and phosphorylates T cell immunoglobulin and mucin domain-1 (Tim-1). Mol. Immunol. 2011, 48:1424-1431.
120. Butcher E.C. The multistep model of leukocyte trafficking: a personal perspective from 15 years later. Leukocyte Trafficking: Molecular Mechanisms, Therapeutic Targets, and Methods 2005, 3-13. Wiley-VCH. A. Hamann, B. Engelhardt (Eds.).
121. Griffith J.W., Luster A.D. Targeting cells in motion: migrating toward improved therapies. Eur. J. Immunol. 2013, 43:1430-1435.
122. Haddad W., et al. P-selectin and P-selectin glycoprotein ligand 1 are major determinants for Th1 cell recruitment to nonlymphoid effector sites in the intestinal lamina propria. J. Exp. Med. 2003, 198:369-377.
123. Sperandio M., et al. Glycosylation in immune cell trafficking. Immunol. Rev. 2009, 230:97-113.
124. Spertini O., et al. P-selectin glycoprotein ligand 1 is a ligand for L-selectin on neutrophils, monocytes, and CD34+ hematopoietic progenitor cells. J. Cell Biol. 1996, 135:523-531.
125. Martinez M., et al. Regulation of PSGL-1 interactions with L-selectin, P-selectin, and E-selectin: role of human fucosyltransferase-IV and -VII. J. Biol. Chem. 2005, 280:5378-5390.
126. Aigner S., et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J. 1998, 12:1241-1251.
127. Green C.E., et al. Shear-dependent capping of L-selectin and P-selectin glycoprotein ligand 1 by E-selectin signals activation of high-avidity beta2-integrin on neutrophils. J. Immunol. 2004, 172:7780-7790.
128. Katayama Y., et al. CD44 is a physiological E-selectin ligand on neutrophils. J. Exp. Med. 2005, 201:1183-1189.
129. Lenter M., et al. Monospecific and common glycoprotein ligands for E- and P-selectin on myeloid cells. J. Cell Biol. 1994, 125:471-481.
130. Steegmaier M., et al. The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature 1995, 373:615-620.
131. McEver R.P. A sulfated address for lymphocyte homing. Nat. Immunol. 2005, 6:1067-1069.
132. Mitoma J. Critical functions of N-glycans in L-selectin-mediated lymphocyte homing and recruitment. Nat. Immunol. 2007, 8:409-418.
133. Romo G.M., et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J. Exp. Med. 1999, 190:803-814.